Several weight-loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Read more...
Hence then, the article about hims hers zealand and roche why these weight loss drug stocks are down today was published today ( ) and is available on Quartz ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hims & Hers, Zealand, and Roche — why these weight loss drug stocks are down today )
Also on site :
- BOXABL Secures Key License in California as a "Commercial Modular Manufacturer" - A Major Milestone for Expansion
- NANOscientific Symposium Series 2025 Concludes Successfully, Marked by a Landmark Celebration of 40 Years of AFM at Stanford
- A Big End to the Year for BP